



Attorney's Docket No.: 13751-056001 / Biogen IdecC045 US CIP2/NsGene119-404-US

IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Dinah W.Y. Sah et al.

Art Unit : 1647

Serial No. : 10/661,984

Examiner : Robert S. Landsman

Filed : September 12, 2003

Title : NOVEL NEUROTROPHIC FACTORS

MAIL STOP AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the references listed on the attached PTO-1449 form.

Under 35 U.S.C. § 120, this application relies on the earlier filing date of U.S. Application Number 09/804,615, filed on March 12, 2001. Those references listed on the enclosed form PTO-1449 that were submitted to or cited by the Office in the prior application are not provided in this application. Furthermore, under 37 C.F.R. § 1.98 (a)(2)(ii), only copies of foreign patent documents and/or non-patent literature are enclosed.

This statement is being filed before the receipt of a first Office Action on the merits.

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

May 24, 2005

Date of Deposit

Signature

Carol Tyrrell

Typed or Printed Name of Person Signing Certificate

Applicant : Dinah W.Y. Sah et al.
Serial No. : 10/661,984
Filed : September 12, 2003
Page : 2 of 2


Attorney's Docket No.: 13751-056001 / Biogen
IdecC045 US CIP2/NsGene119-404-US

Please apply any charges or credits to Deposit Account No. 06-1050, referencing
Attorney Docket No. 13751-056001.

Respectfully submitted,

Date:

May 24, 2005



Jack Brennan
Reg. No. 47,443

Fish & Richardson P.C.
Citigroup Center
52nd Floor
153 East 53rd Street
New York, New York 10022-4611
Telephone: (212) 765-5070
Facsimile: (212) 258-2291

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 13751-056001	Application No. 10/661,984
	Applicant Dinah W.Y. Sah et al.		
	Filing Date September 12, 2003	Group Art Unit 1647	

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	4,883,666	11/28/89	Sabel et al.			
	AB	5,084,350	01/28/92	Chang et al.			
	AC	5,284,761	02/08/94	Aebischer et al.			
	AD	5,496,804	03/05/96	Reed et al.			
	AE	5,618,531	04/08/97	Cherksey			
	AF	5,733,729	03/31/98	Lipshutz et al.			
	AG	5,754,524	05/19/98	Wark			
	AH	5,795,716	08/18/98	Chee et al.			
	AI	5,800,992	09/01/98	Fodor et al.			
	AJ	5,834,029	10/10/98	Bellamkonda et al.			
	AK	5,916,555	06/29/99	Lee et al.			
	AL	6,593,133	07/15/03	Johansen et al.			
	AM	6,734,284	05/11/04	Johansen et al.			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AN	WO 93/06116	04/01/93	WIPO				
	AO	WO 97/08196	03/06/97	WIPO				
	AP	WO 97/11964	04/03/97	WIPO				
	AQ	WO 98/32869	07/30/98	WIPO				
	AR	WO 00/01815	01/13/00	WIPO				
	AS	WO 00/04050	01/27/00	WIPO				
	AT	WO 00/18799	04/06/00	WIPO				
	AU	WO 00/34475	06/15/00	WIPO				
	AV	WO 00/73348	12/07/00	WIPO				
/	AW	WO 02/060929	8/8/02	WIPO				
/	AX	WO 02/078730	10/10/02	WIPO				

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 13751-056001	Application No. 10/661,984
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Dinah W.Y. Sah et al.	
		Filing Date September 12, 2003	Group Art Unit 1647

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AY	Airaksmen et al. (1999), GDNF family neurotrophic factor signaling: four masters, one servant," <i>Mol Cell Neurosci</i> , 13:313-325.
	AZ	Atschul et al. (1997), "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs," <i>Nucl. Acids Res.</i> , 25:3389-3402.
	AAA	Baloh et al. (1998), "Artemm, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFR α 3-RET receptor complex," <i>Neuron</i> , 21:1291-1302.
	ABB	Borodovsky et al. (1995), "Detection of new genes in a bacterial genome using Markov models for three gene classes," <i>Nucl. Acids Res.</i> , 23:3554-3562.
	ACC	Daopin et al. (1993), "Chrystal structure of TGF- β 2 refined at 1.8 A resolution," <i>Proteins</i> , 17:176-192.
	ADD	Eigenbrot and Gerber (1997), "X-ray structure of glial cell-derived neurotrophic factor at 1.9 A resolution and implications for receptor binding," <i>Nat. Struct. Biol.</i> , 4:435-438.
	AEE	Finsen et al. (1992), "Somatostatin and neuropeptide Y in organotypic slice cultures of the rat hippocampus: an immunocytochemical and in situ hybridization study," <i>Neurosci</i> , 47:105-113.
	AFF	Lapchak (1977), "Therapeutic potential for glial cell line-derived neurotrophic factor (GDNF) based upon pharmacological activities in the CNS," <i>Rev. Neurosci.</i> , 7:165-176).
	AGG	Lapchak et al. (1996), "Pharmacological characterization of glial cell line-derived neurotrophic factor (GDNF): implications for GDNF as a therapeutic molecule for treating neurodegenerative diseases," <i>Cell Tissue Res.</i> , 286:179-189.
	AHH	Lin et al. (1993), GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons," <i>Science</i> , 260:1130-1132.
	AII	Lorenz et al. (1996), "Heteromultimeric CLC chloride channels with novel properties," <i>Proc. Natl. Acad. Sci USA</i> , 93: 13362-13366.
	AJJ	Massague et al. (1994), "The TGF- β family and its composite receptor," <i>Trends Cell Biol.</i> , 4:172-178.
	AKK	Masure et al. (1999), "Enovin, a member of the glial cell-line-derived neurotrophic factor (GDNF) family with growth promoting activity on neuronal cells," <i>Eur. J. Biochem</i> , 266:892-902.
	ALL	McDonald and Hendrickson (1993), "A structural superfamily of growth factors containing a cystine knot motif," <i>Cell</i> , 73:421-424.
	AMM	Milbrandt et al. (1998), Persephin, a novel neurotrophic factor related to GDNF and neurturin," <i>Neuron</i> , 20:245-253.
	ANN	Nucleotide Sequence Accession No. AA844072
	AOO	Robertson and Manson (1997), "The GDNF-RET signaling in partnership," <i>Trends Genet.</i> , 13:1-3.
	APP	Saarma and Sariola (1999), <i>Microscopy Res. & Technique</i> , 45:292-302.
	AQQ	Sanicola et al. (1997), "Glial cell line-derived neurotrophic factor-dependent RET activation can be mediated by two different cell-surface accessory proteins," <i>Proc Natl Acad Sci USA</i> , 94:6238-6243.
	ARR	Sauer and Oertel (1994), "Progressive degeneration of nigrostriatal dopamine neurons following intrastratial terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat," <i>Neuroscience</i> , 59:401-415.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 13751-056001	Application No. 10/661,984
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Dinah W.Y. Sah et al.	
		Filing Date September 12, 2003	Group Art Unit 1647

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	ASS	Slooth and Gramsbergen (1995), "Detection of salicylate and its hydroxylated adducts 2.3- and 2.5-dihydroxybenzoic acids as possible indices for in vivo hydroxyl radical formation in combination with catechol- and indoleamines and their metabolites in cerebrospinal fluid and brain tissue," <i>J. Neurosci. Meth.</i> , 60:141-149.
	ATT	Stoppini et al. (1991), "A simple method for organotypic cultures of nervous tissue," <i>J. Neurosci. Methods</i> , 37:173-182.
	AUU	Thompson et al. (1997), "The ClustalX windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools," <i>Nucl. Acids Res.</i> , 25:4876-4882.
	AVV	Unsicker (1996), "GDNF: a cytokine at the interface of TGF-betas and neurotrophins," <i>Cell Tissue Res.</i> , 286:175-178.
	AWW	Von Schwedler et al. (1993), "Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells," <i>J. Virol.</i> , 67:4945-4955.
	AXX	Zufferey et al. (1997), "Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo," <i>Nat. Biotechnol.</i> , 15:871-875.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	